We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cheap, Non-Invasive Blood Test Predicts Alzheimer's Risk 20 Years Ahead of Symptoms

By LabMedica International staff writers
Posted on 20 Sep 2023

At present, Alzheimer's disease is usually identified through signs of cognitive decline, a stage where the brain has already sustained significant damage. More...

Conventional methods for early detection are not only costly but also invasive, typically involving procedures like lumbar punctures that are both physically and emotionally strenuous for the patient. Now, a simple, cheap, and non-invasive blood test may be capable of assessing the likelihood of someone developing Alzheimer's up to two decades before any symptoms appear.

A team of physicists from The Australian National University (ANU, Canberra, Australia) has combined nanotechnology and artificial intelligence (AI) to analyze proteins in the blood for early indicators of neurodegeneration, or specific "biomarkers" signaling the onset of Alzheimer's. Proteins are essentially the foundation of life, containing unique genetic blueprints for each person that offer valuable insights into our health, including the degeneration of brain cells. Locating these proteins with early neurodegeneration markers is like finding a needle in a haystack, according to the researchers.

To tackle this, physicists at ANU have developed an ultra-thin silicon chip embedded with "nanopores," or tiny nanometer-sized holes, that single out proteins for analysis with the aid of a sophisticated AI algorithm. A tiny blood sample is placed on the silicon chip, which is then put into a handheld device roughly the size of a smartphone. This device employs the AI algorithm to sift through the blood sample for protein markers indicative of early-stage Alzheimer's. Notably, the researchers say that the algorithm has the potential to be adapted to screen for various neurological conditions concurrently, such as Parkinson's disease, multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS). The ANU scientists anticipate that this screening method could become accessible within the next five years. The study has been published in the journal Small Methods.

"Blood is a complex fluid that contains more than 10,000 different biomolecules. By employing advanced filtration techniques and harnessing our nanopore platform, combined with our intelligent machine learning algorithms, we may be able to identify even the most elusive proteins," said ANU Ph.D. researcher Shankar Dutt.

Related Links:
ANU 


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Portable Electronic Pipette
Mini 96
New
Laboratory Software
ArtelWare
New
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.